Oral, colonic-release low-molecular-weight heparin

An initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis

L. Pastorelli, S. Saibeni, L. Spina, C. Signorelli, G. Celasco, R. De Franchis, M. Vecchi

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: Efficacy of heparin and low-molecular-weight heparins (LMWHs) in inflammatory bowel disease (IBD) treatment has been suggested. The multimatrix oral formulation MMX releases active drugs in the colon, avoiding systemic absorption. Parnaparin sodium is the LMWH chosen to be carried in the MMX formulation. Aim: To assess the safety of three different oral dosages (70, 140 and 210 mg once daily) of Parnaparin-MMX (CB-01-05) in left-sided ulcerative colitis (UC). Methods: Left-sided UC patients, with a mild-to-moderate relapse were enrolled. All patients received Parnaparin-MMX for 8 weeks. Clinical Activity Index (CAI), Disease Activity Index (DAI), Endoscopic Activity Index and IBD-QoL were assessed throughout the study. A strict clinical and laboratory follow-up, including assessment of anti-factor Xa activity, was performed. Clinical remission was defined as CAI

Original languageEnglish
Pages (from-to)581-588
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume28
Issue number5
DOIs
Publication statusPublished - Sep 2008

Fingerprint

Low Molecular Weight Heparin
Ulcerative Colitis
Inflammatory Bowel Diseases
Factor Xa
Therapeutics
Heparin
Colon
Safety
Recurrence
parnaparin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Oral, colonic-release low-molecular-weight heparin : An initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis. / Pastorelli, L.; Saibeni, S.; Spina, L.; Signorelli, C.; Celasco, G.; De Franchis, R.; Vecchi, M.

In: Alimentary Pharmacology and Therapeutics, Vol. 28, No. 5, 09.2008, p. 581-588.

Research output: Contribution to journalArticle

@article{deb6e4eb985f42c89aad89bad7809b67,
title = "Oral, colonic-release low-molecular-weight heparin: An initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis",
abstract = "Background: Efficacy of heparin and low-molecular-weight heparins (LMWHs) in inflammatory bowel disease (IBD) treatment has been suggested. The multimatrix oral formulation MMX releases active drugs in the colon, avoiding systemic absorption. Parnaparin sodium is the LMWH chosen to be carried in the MMX formulation. Aim: To assess the safety of three different oral dosages (70, 140 and 210 mg once daily) of Parnaparin-MMX (CB-01-05) in left-sided ulcerative colitis (UC). Methods: Left-sided UC patients, with a mild-to-moderate relapse were enrolled. All patients received Parnaparin-MMX for 8 weeks. Clinical Activity Index (CAI), Disease Activity Index (DAI), Endoscopic Activity Index and IBD-QoL were assessed throughout the study. A strict clinical and laboratory follow-up, including assessment of anti-factor Xa activity, was performed. Clinical remission was defined as CAI",
author = "L. Pastorelli and S. Saibeni and L. Spina and C. Signorelli and G. Celasco and {De Franchis}, R. and M. Vecchi",
year = "2008",
month = "9",
doi = "10.1111/j.1365-2036.2008.03757.x",
language = "English",
volume = "28",
pages = "581--588",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

TY - JOUR

T1 - Oral, colonic-release low-molecular-weight heparin

T2 - An initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis

AU - Pastorelli, L.

AU - Saibeni, S.

AU - Spina, L.

AU - Signorelli, C.

AU - Celasco, G.

AU - De Franchis, R.

AU - Vecchi, M.

PY - 2008/9

Y1 - 2008/9

N2 - Background: Efficacy of heparin and low-molecular-weight heparins (LMWHs) in inflammatory bowel disease (IBD) treatment has been suggested. The multimatrix oral formulation MMX releases active drugs in the colon, avoiding systemic absorption. Parnaparin sodium is the LMWH chosen to be carried in the MMX formulation. Aim: To assess the safety of three different oral dosages (70, 140 and 210 mg once daily) of Parnaparin-MMX (CB-01-05) in left-sided ulcerative colitis (UC). Methods: Left-sided UC patients, with a mild-to-moderate relapse were enrolled. All patients received Parnaparin-MMX for 8 weeks. Clinical Activity Index (CAI), Disease Activity Index (DAI), Endoscopic Activity Index and IBD-QoL were assessed throughout the study. A strict clinical and laboratory follow-up, including assessment of anti-factor Xa activity, was performed. Clinical remission was defined as CAI

AB - Background: Efficacy of heparin and low-molecular-weight heparins (LMWHs) in inflammatory bowel disease (IBD) treatment has been suggested. The multimatrix oral formulation MMX releases active drugs in the colon, avoiding systemic absorption. Parnaparin sodium is the LMWH chosen to be carried in the MMX formulation. Aim: To assess the safety of three different oral dosages (70, 140 and 210 mg once daily) of Parnaparin-MMX (CB-01-05) in left-sided ulcerative colitis (UC). Methods: Left-sided UC patients, with a mild-to-moderate relapse were enrolled. All patients received Parnaparin-MMX for 8 weeks. Clinical Activity Index (CAI), Disease Activity Index (DAI), Endoscopic Activity Index and IBD-QoL were assessed throughout the study. A strict clinical and laboratory follow-up, including assessment of anti-factor Xa activity, was performed. Clinical remission was defined as CAI

UR - http://www.scopus.com/inward/record.url?scp=48449091370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48449091370&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2008.03757.x

DO - 10.1111/j.1365-2036.2008.03757.x

M3 - Article

VL - 28

SP - 581

EP - 588

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 5

ER -